News

Number of news items returned: 21 to 40 records of 478

"Growth and Walker Capital Features in the SMH and AGE"

21 March 2019

(1237 views)

     "Growth and Walker Capital Features in the SMH and AGE Following the Royal Commission into the banking sector, investors are looking ...

BlueMount Capital Secures Expansion Funding for Elite Military Fitness

14 March 2019

(1974 views)

   BlueMount Capital Secures Expansion Funding for Elite Military Fitness   "I am delighted to announce that we have secured AUD $3.5 million ...

Readers, News and Updates - Funding Strategies Connect March 2019

14 March 2019

(2047 views)

   Readers, News and Updates - Funding Strategies Connect March 2019   Dear Reader, Welcome to the March 2019 edition of Funding Strategies Connect! We ...

Guarda wins big at World of Concrete Trade Show

13 March 2019

(1997 views)

  "Guarda wins big at World of Concrete Trade Show   The Guarda Edge Powercutter has just won the award for "Most Innovative ...

Qponics: Progress on the upgrade of the pilot algae farm in Brisbane into a small-scale production facility

28 February 2019

(2308 views)

  "Qponics: Progress on the upgrade of the pilot algae farm in Brisbane into a small-scale production facility   The sky-blue coloured lining for ...

Podcast: Learning Comes First! (ft. Manish Goklaney, Co-Founder of Learn Primary)

25 February 2019

(2237 views)

   Podcast: Learning Comes First! (ft. Manish Goklaney, Co-Founder of Learn Primary)   Today on Eden Exchanges we spoke to Manish Goklaney, Co-Founder ...

"Silicosis death dust audit reveals 'major epidemic worse than asbestos'"

21 February 2019

(2232 views)

  "Silicosis death dust audit reveals 'major epidemic worse than asbestos'  ABC News reported on 21 February 2019: "An audit of Queensland's manufacturing ...

Director Briefing with Manish Goklaney from Learn Primary

19 February 2019

(2776 views)

In this Director Briefing, Manish Goklaney, Co-Founder of Learn Primary Pty Ltd, discusses: Learn Primary’s objective to improve learning for children ...

Podcast: The Road Most Travelled (ft. David Keir from Freedom Road Travel Group – Discusses Strategy and Expansion Plans)

19 February 2019

(2681 views)

   Podcast: The Road Most Travelled (ft. David Keir from Freedom Road Travel Group – Discusses Strategy and Expansion Plans)   Today on ...

"Freedom Road Travel plans capital raise to expand China-focused business to US – CEO"

12 February 2019

(2854 views)

   "Freedom Road Travel plans capital raise to expand China-focused business to US – CEO   Freedom Road Travel Group (FRTG), a Hong ...

"Learn Primary could seek to raise capital in 4Q19 to enter New Zealand, Canada - CEO"

08 February 2019

(3104 views)

  "Learn Primary could seek to raise capital in 4Q19 to enter New Zealand, Canada - CEO   Learn Primary, a private Australian ...

Readers, Happy new year - Funding Strategies Connect January and February 2019

05 February 2019

(3175 views)

  Reader, Happy new year - Funding Strategies Connect Jan/Feb 2019   Dear Readers, Happy New Year 2019 - The Year of the Pig! We ...

Learn Primary - January 2019 Update and Announcements

31 January 2019

(3309 views)

   "Learn Primary - January 2019 Update and Announcements   Over the last quarter Learn Primary has had significant achievements which the Company ...

"Progress on the upgrade of the pilot algae farm in Brisbane into a small-scale production facility"

30 January 2019

(3293 views)

  "Progress on the upgrade of the pilot algae farm in Brisbane into a small-scale production facility The small ultrafiltration system continues ...

“Guarda Systems receives strong interest in products at World of Concrete Trade Show in the US”

30 January 2019

(3292 views)

  “Guarda Systems receives strong interest in products at World of Concrete Trade Show in the US” "Guarda Systems attended the World ...

"FREEDOM ROAD TRAVEL SECURE QUEENSLAND RUGBY UNION PARTNERSHIP"

28 January 2019

(3241 views)

  " FREEDOM ROAD TRAVEL SECURE QUEENSLAND RUGBY UNION PARTNERSHIP  Freedom Road Travel has gone from strength to strength in both the domestic ...

"Helio Lending in Hong Kong"

24 January 2019

(3344 views)

  "Helio Lending In Hong Kong   Helio Lending has been in attendance at the Asian Financial Forum in Hong Kong, represented by ...

Director Briefing with Dr Graeme Barnett from Qponics Limited

18 January 2019

(3630 views)

  In this Director Briefing, Dr Graeme Barnett, CEO and Managing Director of Qponics Limited ("Qponics", "the Company") discusses: Background of Qponics ...

Podcast: Delivering an Elite Business, Military Style (Ft. Scott Freeman of EMF, Elite Military Fitness)

20 December 2018

(3611 views)

  Podcast: Delivering an Elite Business, Military Style (Ft. Scott Freeman of EMF, Elite Military Fitness)   Today on Eden Exchanges we spoke ...

Guarda Releases Powerful Saw Dust Comparison Video

18 December 2018

(4694 views)

    Guarda Releases Powerful Saw Dust Comparison Video    "We are very excited that our brand new Guarda Edge Powercutter will be in ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625